Microbix Biosystems Inc. (MBX) — Q3 2025 results
The company reported an operating loss of -$23.9 million (year-over-year change +22.0%). Net loss attributable to common shareholders was -$21.6 million, and diluted loss per share was -0.63, a -77.34% year-over-year change.
Key takeaways: Microbix Biosystems Inc. (MBX) showed a meaningful decline in revenue and gross profit in Q3 2025 while recording substantial operating and net losses. The company’s sizable cash balance of $223.1 million contrasts with ongoing negative operating cash flow, and capital expenditures increased notably in the quarter.
Microbix Biosystems Inc. Insider Trading Activity
Microbix Biosystems Inc. insiders have traded $MBX stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MBX stock by insiders over the last 6 months:
- PATRICK J HERON purchased 666,666 shares for an estimated $11,999,988
- P. KENT HAWRYLUK (President & CEO) purchased 20,000 shares for an estimated $272,790
- STEVEN L. HOERTER purchased 20,000 shares for an estimated $264,984
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Microbix Biosystems Inc. Hedge Fund Activity
We have seen 66 institutional investors add shares of Microbix Biosystems Inc. stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,556,708 shares (+112.8%) to their portfolio in Q3 2025, for an estimated $44,742,390
- KYNAM CAPITAL MANAGEMENT, LP added 2,000,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $35,000,000
- MPM BIOIMPACT LLC removed 1,294,416 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $22,652,280
- CITADEL ADVISORS LLC added 996,083 shares (+inf%) to their portfolio in Q3 2025, for an estimated $17,431,452
- ECOR1 CAPITAL, LLC added 973,810 shares (+84.7%) to their portfolio in Q3 2025, for an estimated $17,041,675
- DEEP TRACK CAPITAL, LP added 961,408 shares (+43.9%) to their portfolio in Q3 2025, for an estimated $16,824,640
- BLACKROCK, INC. added 945,915 shares (+93.5%) to their portfolio in Q3 2025, for an estimated $16,553,512
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Microbix Biosystems Inc. Analyst Ratings
Wall Street analysts have issued reports on $MBX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Sell" rating on 12/04/2025
- Guggenheim issued a "Buy" rating on 11/10/2025
- TD Cowen issued a "Buy" rating on 11/04/2025
- Mizuho issued a "Outperform" rating on 09/24/2025
- Oppenheimer issued a "Outperform" rating on 09/23/2025
- Jefferies issued a "Buy" rating on 08/15/2025
To track analyst ratings and price targets for Microbix Biosystems Inc., check out Quiver Quantitative's $MBX forecast page.
Microbix Biosystems Inc. Price Targets
Multiple analysts have issued price targets for $MBX recently. We have seen 6 analysts offer price targets for $MBX in the last 6 months, with a median target of $53.0.
Here are some recent targets:
- Corinne Johnson from Goldman Sachs set a target price of $18.0 on 12/04/2025
- Seamus Fernandez from Guggenheim set a target price of $77.0 on 11/10/2025
- Srikripa Devarakonda from Truist Securities set a target price of $50.0 on 10/15/2025
- Uy Ear from Mizuho set a target price of $56.0 on 09/24/2025
- Trevor Allred from Oppenheimer set a target price of $80.0 on 09/23/2025
- Roger Song from Jefferies set a target price of $36.0 on 08/15/2025
